Pancragen
KEDW peptide, Lys-Glu-Asp-Trp, Lys-Glu-Asp-Trp-NH2, KEDW-NH2, pancreatic bioregulator peptide
Pancragen is a four-amino-acid Khavinson peptide directed at the endocrine pancreas and promoted for glucose regulation. It has the most developed evidence base of the organ-specific bioregulators, including work in rats, aged rhesus monkeys and one small human study in elderly people with type 2 diabetes. That evidence is still thin, unrandomised at the human level and confined to the originating network.
Mechanism
Pancragen is assigned within the Khavinson framework to pancreatic tissue, and the proposed mechanism is the standard one for the series: entry into the nucleus and direct interaction with promoter DNA, regulating transcription of genes governing islet cell differentiation and function. Fluorescence and oligonucleotide-binding work on the series, which included KEDW among the peptides tested, has been offered in support, as has a 2023 computational study proposing uptake via LAT and PEPT transporters.
The reported cellular effect is on pancreatic cell differentiation. In ageing pancreatic cell culture, KEDW was reported to increase expression of markers associated with islet cell identity, offered as evidence that it restores differentiation capacity lost with age. In diabetic rodent models, effects were reported on blood glucose, capillary permeability and cell adhesion.
The tryptophan at position four is notable. Tryptophan is bulky, aromatic and the rarest of the twenty proteinogenic amino acids, and its presence gives KEDW a distinctive absorbance profile useful for analytical detection. It also makes KEDW more lipophilic than the other members of the series, which is at least a plausible physical basis for differing behaviour, though this has not been formally linked to any reported activity. The C-terminal amide, which the NLM record treats as definitional, would additionally block carboxypeptidase degradation, so the canonical form of this peptide is more protease-resistant than most of the series.
What the research shows
The animal work is the most concrete in the organ-specific series. A 2007 rat study reported that Pancragen lowered blood glucose and improved capillary permeability and adhesion measures in experimental diabetes mellitus. More interesting is the primate work: studies in old female rhesus monkeys reported effects on pancreatic endocrine function and correction of impaired glucose tolerance. Non-human primate data is rare in this literature and represents a genuine step up in model relevance, though the studies are small, published in a Russian-language gerontology journal with limited international readership, and have not been independently replicated.
The human evidence consists of a single 2011 report in Bulletin of Experimental Biology and Medicine. It examined 30 healthy older people and 33 older patients with type 2 diabetes, found nocturnal melatonin production reduced by about 70 per cent in the diabetic group, and reported that in diabetic patients Pancragen significantly reduced fasting glucose, glucose on a standard tolerance test, plasma insulin and an insulin resistance index, while diabetic patients not receiving Pancragen showed no change in carbohydrate metabolism indices. So there was an untreated comparison group, which is more than the draft description of a wholly uncontrolled study allowed. But no randomisation, blinding, allocation concealment or pre-registration is reported, the numbers are small, it comes from the originating network, and it has never been replicated. There is no randomised controlled trial and no registered clinical trial.
The framing that matters for a reader considering this compound: type 2 diabetes and impaired glucose tolerance have well-characterised treatments with demonstrated effects on hard outcomes, and glucose is easy to measure. A peptide with one small unrandomised human study is not a substitute, and self-treating glucose dysregulation without monitoring is specifically hazardous.
Evidence assessment
Limited evidence
A single small human study with an untreated comparison group but no randomisation or blinding exists alongside rodent and non-human primate data, all from the originating research network, with no randomised trial and no independent replication.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Prospects of using pancragen for correction of metabolic disorders in elderly people Limited evidence
In patients with type 2 diabetes, Pancragen significantly reduced fasting glucose, glucose on a standard tolerance test, plasma insulin and an insulin resistance index; untreated patients showed no change. Nocturnal melatonin production was about 70 per cent lower in the diabetic group than in healthy peers.
Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys Preclinical only
Pancragen was reported to improve glucose tolerance in aged monkeys.
Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys Preclinical only
Reported changes in pancreatic endocrine function measures after Pancragen administration.
Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus Preclinical only
Pancragen reduced blood glucose and altered capillary permeability and adhesion measures.
Effects of pancragen on the differentiation of pancreatic cells during their ageing Preclinical only
KEDW increased expression of islet cell differentiation markers in ageing pancreatic cell cultures.
Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters Preclinical only
KEDW was among the ultrashort peptides modelled, with the authors proposing transporter-mediated cellular uptake for the series.
Safety
No formal safety characterisation. The rodent and primate studies did not report overt toxicity but were not designed as safety studies and used small numbers. There is no human adverse event database, no dose-ranging and no toxicology. A specific hazard applies here that does not apply to most compounds in this class, and the human study makes it concrete rather than theoretical: Pancragen was reported to significantly lower fasting glucose, tolerance-test glucose and plasma insulin in elderly patients with type 2 diabetes. A substance with that reported effect, taken by someone also on glucose-lowering medication and without monitoring, carries a hypoglycaemia risk that has never been characterised and for which no interaction data exist.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation. Supply for human use engages the Human Medicines Regulations 2012 regardless of a 'research use only' label. |
| United States | Not approved by the FDA, never studied under an investigational new drug application, absent from clinical trial registries. Sold as a research chemical. |
| WADA (sport) | Not individually named on the Prohibited List but captured by section S0 (non-approved substances), prohibited at all times. |
Questions
One small non-randomised study in elderly patients with type 2 diabetes reported reductions in fasting glucose, tolerance-test glucose, plasma insulin and insulin resistance, with no change in untreated patients. Without randomisation or blinding that design cannot fully separate drug effect from expectation or regression to the mean, and it has never been replicated. No randomised controlled trial has been conducted.
It has the most developed record of the organ-specific bioregulators, including rat and aged rhesus monkey studies plus one human study. That still falls well short of what would be needed to establish efficacy, and all of it comes from the originating network.
This has never been studied and carries a specific hazard. The one human study reported significant glucose and insulin lowering in people with type 2 diabetes, so combining it with prescribed glucose-lowering therapy without monitoring risks hypoglycaemia. No interaction data exist.
The one-letter code for Pancragen's sequence: lysine, glutamate, aspartate, tryptophan. The canonical published form carries a C-terminal amide (Lys-Glu-Asp-Trp-NH2), which is how the US National Library of Medicine indexes the compound.